WORK Medical Technology Group LTD (WOK) AI Stock Analysis
WOK AI stock analysis summary
AI ResearchWORK Medical Technology Group LTD manufactures and exports medical consumables and devices. Between FY2021 and FY2025, annual revenue contracted from $45.9M to $9.8M, reflecting a 5-year revenue CAGR of -28.5%. Supported by a market capitalization of $4.9M, the company generated $10.7M in trailing twelve-month revenue alongside a net profit margin of -41.9%.
- Market cap
- $4.9M
- Revenue (TTM)
- $10.7M
- P/E
- —
- 1Y return
- — S&P 500 16.8%
- Avg. target
- —
Bull case
- Operating cash flow turned positive to $6.2M in FY2025, delivering $4.9M in free cash flow.
- Quarterly revenue grew 19.1% year-over-year during the quarter ended June 30, 2026.
- The stock trades at a price-to-book ratio of 0.3x and a price-to-sales ratio of 0.5x.
Bear case
- Revenue fell from $45.9M in FY2021 to $9.8M in FY2025, registering a 5-year CAGR of -28.5%.
- Shares dropped 99.5% year-to-date to close at $1.09, far below the 52-week high of $17800.00.
- Trailing twelve-month operating margin was -65.3%, leading to an EPS of -$51993.25.
What WORK Medical Technology Group LTD does
WORK Medical Technology Group LTD, founded in 2002 and based in Hangzhou City, China, manufactures and sells medical consumables and devices domestically and internationally. Its portfolio includes medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, disposable breathing circuits, laryngeal mask airways, and anesthetic kits. The company also offers KN95 masks, visualized prostatic dilatation catheters, nebulizer kits, personal protective equipment, skincare products, and non-powered air-purifying respirators. It exports products to approximately 30 countries across Asia, Africa, Europe, North America, South America, and Oceania, and maintains a strategic cooperation agreement with Shanghai Novabioplus Biotechnology Co., Ltd.
Growth and profitability
Revenue contracted steadily from $45.9M in FY2021 to $19.7M in FY2022, $13.6M in FY2023, $11.5M in FY2024, and $9.8M in FY2025, marking a 5-year revenue CAGR of -28.5%. Operating margin declined from 16.7% in FY2021 to -25.3% in FY2025, while net income fell from $6.0M to -$1.1M over the same period. Across the trailing twelve months, revenue totaled $10.7M with an operating margin of -65.3% and a net profit margin of -41.9%. In the latest quarter ended June 30, 2026, quarterly revenue increased 19.1% year-over-year, while quarterly earnings declined 95.0%.
Balance sheet and cash flow
As of June 30, 2026, WORK Medical Technology Group LTD held $3.3M in cash and short-term investments against total debt of $6.6M, resulting in net debt of $3.4M. Shareholders' equity stood at $30.1M alongside total assets of $48.3M, with a current ratio of 1.37 and a debt-to-equity ratio of 0.22. During FY2025, operating cash flow turned positive to $6.2M, capital expenditures were $1.3M, and free cash flow reached $4.9M.
Valuation and performance
At the last close of $1.09 on October 16, 2026, WOK carried a market capitalization of $4.9M and an enterprise value of $11.7M. The stock trades at a price-to-sales multiple of 0.5x, well below the median of its US-listed Healthcare peers of 4.1x, and a price-to-book multiple of 0.3x. Its EV/EBITDA multiple of 23.1x sits above the peer median of 12.0x. Year-to-date, WOK shares returned -99.5% and traded 98.5% below their 200-day average, while the S&P 500 recorded a 1-year return of 16.8%.
What analysts expect
WORK Medical Technology Group LTD has no Wall Street consensus recommendations, price targets, or earnings estimates available. For the trailing twelve months ended June 30, 2026, the company posted diluted EPS of -$51993.25. Insiders hold 0.0% of shares, institutional investors own 0.5%, and short interest represents 3.1% of float. The company has not provided a scheduled date for its next quarterly financial results.
Key risks and what to watch
- Total debt of $6.6M as of June 30, 2026 exceeded cash and short-term investments of $3.3M, creating net debt of $3.4M.
- Quarterly earnings fell 95.0% year-over-year in the period ended June 30, 2026.
- The stock exhibits high price volatility with a beta of 1.74 and minimal institutional ownership of 0.5%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this WOK AI stock analysis
This page is an AI-written research summary of WORK Medical Technology Group LTD (WOK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: WOK income statement, WOK balance sheet, WOK key metrics, WOK chart. See the WOK stock overview for the latest quote and news.
WOK AI stock analysis FAQ
What products does WORK Medical Technology Group LTD manufacture?
The company produces medical consumables and devices, including face masks, breathing circuits, anesthetic kits, tourniquets, and non-powered air-purifying respirators, serving customers across approximately 30 countries.
What was WOK's revenue in FY2025?
In FY2025, revenue was $9.8M, representing a 14.4% decline compared to $11.5M reported in FY2024.
What is WORK Medical Technology Group LTD's cash and debt position?
As of June 30, 2026, the company held $3.3M in cash and short-term investments against $6.6M in total debt, yielding net debt of $3.4M.
Does WOK pay a dividend?
The company does not pay a dividend on its shares.